Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Bladder Cancer

Free Subscription 11.07.2022 1 Actas Urol Esp (Engl Ed) 1 Ann Diagn Pathol 3 Ann Surg Oncol 3 Anticancer Res 5 Arch Ital Urol Androl 1 Asian J Endosc Surg 1 Biochem Biophys Res Commun 1 Biol Pharm Bull 5 BJU Int 1 BMC Cancer 1 Br J Cancer 1 Br J Dermatol 1 Cancer Drug Resist 1 Comput Biol Med 1 Comput Math Methods Med 1 Contrast Media Mol Imaging 1 Curr Med Sci 1 Diagn Cytopathol 1 Dis Markers 1 Discov Oncol 1 Eur Rev Med Pharmacol Sci 2 Eur Urol 1 Eur Urol Focus 1 Eur Urol Oncol 1 Evid Based Complement Alternat Med 1 Front Cell Dev Biol 1 Front Genet 1 Front Med (Lausanne) 1 Front Oncol 1 Gene 1 IJU Case Rep 1 Indian J Surg Oncol 1 Int J Med Robot 1 Int J Mol Med 1 Int J Radiat Oncol Biol Phys 1 Int J Surg Pathol 5 Int J Urol 1 Investig Clin Urol 1 J Adv Res 1 J Chromatogr A 1 J Immunother Cancer 1 J Rheumatol 1 J Transl Med 1 Mayo Clin Proc 3 Medicine (Baltimore) 1 Nat Rev Urol 1 Oncogene 1 Oncologist 1 Pharmacoepidemiol Drug Saf 1 PLoS Genet 2 PLoS One 1 Sci Rep 1 Ther Adv Med Oncol 1 World J Surg Oncol 2 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Actas Urol Esp (Engl Ed)

1. YANG Y, Hu H, Chen L, Zhang H, et al
   A new survival model based on ferroptosis-related genes (FRGS) for prognostic prediction in bladder cancer.
   Actas Urol Esp (Engl Ed). 2022 Jun 29. pii: S2173-5786(22)00046.
   PubMed         Abstract available
   
   

   
   Ann Diagn Pathol

2. WENG M, Bai Y, Xu L, Chang C, et al
   Comparison of PD-L1 detection methods, platforms and reagents in bladder cancer.
   Ann Diagn Pathol. 2022;60:151986.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. MORI K, Schuettfort VM, Katayama S, Laukhtina E, et al
   Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
   Ann Surg Oncol. 2022;29:5307-5316.
   PubMed         Abstract available
   
   
4. BITCON C, Whalen S, Coleman J, Rendon R, et al
   Utility of Postoperative Serial Renal Function Monitoring in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma.
   Ann Surg Oncol. 2022;29:5333-5337.
   PubMed         Abstract available
   
   
5. MORI K, Schuettfort VM, Egawa S, Comperat E, et al
   ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
   Ann Surg Oncol. 2022;29:5317-5318.
   PubMed        
   
   

   
   Anticancer Res

6. INOUE S, Sassa N, Kawanishi H, Yuguchi Y, et al
   Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer.
   Anticancer Res. 2022;42:3627-3636.
   PubMed         Abstract available
   
   
7. DENG F, Kong MX, Lai J
   Synchronous Penile Squamous Cell Carcinoma, Bladder Urothelial Carcinoma and Prostate Adenocarcinoma Diagnosed in One Procedure.
   Anticancer Res. 2022;42:3601-3605.
   PubMed         Abstract available
   
   
8. WALLACE B, Dekalo S, Kabha M, Mintz I, et al
   Can We Predict a Higher Risk of Urothelial Bladder Cancer With a Simple Blood Test?
   Anticancer Res. 2022;42:3569-3573.
   PubMed         Abstract available
   
   

   
   Arch Ital Urol Androl

9. MEHRNOUSH V, De Lima SG, Kotb A, Hyndman ME, et al
   The association of bladder cancer and Cannabis: A systematic review.
   Arch Ital Urol Androl. 2022;94:248-251.
   PubMed         Abstract available
   
   
10. ARIAFAR A, Salehipour M, Zeyghami S, Rezaei M, et al
    The effect of retroperitonealization of ureteroileal anastomosis on perioperative complications of radical cystectomy with ileal conduit urinary diversion.
    Arch Ital Urol Androl. 2022;94:150-154.
    PubMed         Abstract available
    
    
11. MALINARIC R, Mantica G, Balzarini F, Terrone C, et al
    Extraperitoneal cystectomy with ureterocutaneostomy derivation in fragile patients - should it be performed more often?
    Arch Ital Urol Androl. 2022;94:144-149.
    PubMed         Abstract available
    
    
12. PEREIRA JN, Reis JD, Braga I, Freitas R, et al
    Variant histologies of urothelial carcinoma: Does it change the survival outcomes in patients managed with radical cystectomy?
    Arch Ital Urol Androl. 2022;94:138-143.
    PubMed         Abstract available
    
    
13. LEONARDI R, Calarco A, Falcone L, Grasso V, et al
    Endoscopic laser en bloc removal of bladder tumor. Surgical radicality and improvement of the pathological diagnostic accuracy.
    Arch Ital Urol Androl. 2022;94:134-137.
    PubMed         Abstract available
    
    

    
    Asian J Endosc Surg

14. MORIZANE S, Honda M, Yumioka T, Iwamoto H, et al
    Technique of en bloc resection of the membranous urethra and bladder during robot-assisted radical cystectomy in patients without simultaneous urethrectomy.
    Asian J Endosc Surg. 2022;15:683-687.
    PubMed         Abstract available
    
    

    
    Biochem Biophys Res Commun

15. LIU X, He Y, Tong Y, Huang Q, et al
    PODNL1 promotes cell migration and regulates the epithelial/mesenchymal transition process in bladder cancer.
    Biochem Biophys Res Commun. 2022;620:165-172.
    PubMed         Abstract available
    
    

    
    Biol Pharm Bull

16. ZHOU Q, Wu WW, Yu CL, Wang P, et al
    Saikosaponin A Inhibits Growth of Human Bladder Carcinoma T24 and 5637 Cells Both in Vitro and in Vivo.
    Biol Pharm Bull. 2022;45:863-871.
    PubMed         Abstract available
    
    

    
    BJU Int

17. DADIKHI K, Mueller F, Montani M, Thalmann GN, et al
    Case of the Month from the University Hospital of Bern, Switzerland: Urothelial carcinoma in an orthotopic neobladder: reported cases and pathophysiological hypotheses.
    BJU Int. 2022;130:38-42.
    PubMed        
    
    
18. LOIZZO D, Pandolfo SD, Del Giudice F, Cerrato C, et al
    Ureteroscopy and tailored treatment of upper tract urothelial cancer: recent advances and unmet needs.
    BJU Int. 2022;130:35-37.
    PubMed        
    
    
19. MAIBOM SL, Roder MA, Aasvang EK, Rohrsted M, et al
    Open vs robot-assisted radical cystectomy (BORARC): a double-blinded, randomised feasibility study.
    BJU Int. 2022;130:102-113.
    PubMed         Abstract available
    
    
20. AHMADI H, Ladi-Seyedian SS, Konety B, Pohar K, et al
    Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry.
    BJU Int. 2022;130:62-67.
    PubMed         Abstract available
    
    
21. GRAHN A, Eisfeldt J, Malm C, Foroughi Asl H, et al
    Genomic profile - a possible diagnostic and prognostic marker in upper tract urothelial carcinoma.
    BJU Int. 2022;130:92-101.
    PubMed         Abstract available
    
    

    
    BMC Cancer

22. KIM GT, Kim EY, Shin SH, Lee H, et al
    Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma.
    BMC Cancer. 2022;22:727.
    PubMed         Abstract available
    
    

    
    Br J Cancer

23. TOMIYAMA E, Fujita K, Matsuzaki K, Narumi R, et al
    EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer.
    Br J Cancer. 2022 Jul 6. pii: 10.1038/s41416-022-01860.
    PubMed         Abstract available
    
    

    
    Br J Dermatol

24. PENNY CL, Quow K, Rundle CW, Al-Rohil RN, et al
    Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
    Br J Dermatol. 2022 Jan 19. doi: 10.1111/bjd.21022.
    PubMed        
    
    

    
    Cancer Drug Resist

25. RUIZ DE PORRAS V
    Natural bioactive compounds: a potential therapeutic strategy to sensitize bladder cancer to cisplatin treatment?
    Cancer Drug Resist. 2022;5:339-343.
    PubMed         Abstract available
    
    

    
    Comput Biol Med

26. ZHENG X, Xu H, Lin T, Tan P, et al
    CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
    Comput Biol Med. 2022;147:105727.
    PubMed         Abstract available
    
    

    
    Comput Math Methods Med

27. HU K, Zhu J, Li P, Ying L, et al
    Multiorientation Simultaneous Computation of Back-Projection CT Image Reconstruction Algorithm in Staging Diagnosis of Bladder Cancer.
    Comput Math Methods Med. 2022;2022:6731491.
    PubMed         Abstract available
    
    

    
    Contrast Media Mol Imaging

28. KE H, Qiu D, Cong Z
    Prognosis Analysis and Perioperative Research of Elderly Patients with Non-Muscle-Invasive Bladder Cancer under Computed Tomography Image of Three-Dimensional Reconstruction Algorithm.
    Contrast Media Mol Imaging. 2022;2022:6168528.
    PubMed         Abstract available
    
    

    
    Curr Med Sci

29. HU QG, Yang Z, Chen JW, Kazobinka G, et al
    MiR-183-5p-PNPT1 Axis Enhances Cisplatin-induced Apoptosis in Bladder Cancer Cells.
    Curr Med Sci. 2022 Jul 5. pii: 10.1007/s11596-022-2580.
    PubMed         Abstract available
    
    

    
    Diagn Cytopathol

30. YUAN L, Gero M, Zia S, Aryal SC, et al
    Cyto-histo correlation and false-negative urine: Before and after the Paris system for reporting urinary cytology.
    Diagn Cytopathol. 2022;50:404-410.
    PubMed         Abstract available
    
    

    
    Dis Markers

31. CHI BJ, Sun Y, Quan LL, Zhao JT, et al
    Metformin Can Enhance the Inhibitory Effect of Olaparib in Bladder Cancer Cells.
    Dis Markers. 2022;2022:5709259.
    PubMed         Abstract available
    
    

    
    Discov Oncol

32. HUANG W, Zhang C, Xiong S, Zhou X, et al
    miR-1307-5p suppresses proliferation and tumorigenesis of bladder cancer via targeting MDM4 and the Hippo signaling pathway.
    Discov Oncol. 2022;13:57.
    PubMed         Abstract available
    
    

    
    Eur Rev Med Pharmacol Sci

33. ZHAO X, Li D, Zhao ST, Zhang Y, et al
    MiRNA-616 aggravates the progression of bladder cancer by regulating cell proliferation, migration and apoptosis through downregulating SOX7.
    Eur Rev Med Pharmacol Sci. 2022;26:4158.
    PubMed         Abstract available
    
    

    
    Eur Urol

34. ADELEKE S, Tocco B, Kasivisvanathan V
    Re: Chemoradiotherapy in Muscle-invasive Bladder Cancer (BC2001): 10-year Follow-up of a Phase 3 Randomised Controlled Trial.
    Eur Urol. 2022 Jul 1. pii: S0302-2838(22)02470.
    PubMed        
    
    
35. TAKAHASHI T
    Re: Ekaterina Laukhtina, Shahrokh F. Shariat. Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.o
    Eur Urol. 2022 Jul 1. pii: S0302-2838(22)02466.
    PubMed        
    
    

    
    Eur Urol Focus

36. STANGL-KREMSER J, Lambertini L, Di Maida F, Martinez-Fundichely A, et al
    Enhancing Recovery After Major Bladder Cancer Surgery: Comprehensive Review and Assessment of Application of the Enhanced Recovery After Surgery Guidelines.
    Eur Urol Focus. 2022 Jun 27. pii: S2405-4569(22)00133.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

37. HEMENWAY G, Lewis B, Ghatalia P, Anari F, et al
    Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy.
    Eur Urol Oncol. 2022 Jul 2. pii: S2588-9311(22)00107.
    PubMed         Abstract available
    
    

    
    Evid Based Complement Alternat Med

38. SHANG X, Na X, Wang L, Yang Z, et al
    Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells.
    Evid Based Complement Alternat Med. 2022;2022:8110796.
    PubMed         Abstract available
    
    

    
    Front Cell Dev Biol

39. WANG C, Wan H, Zhang H, Yang B, et al
    Characterization of Ligand-Receptor Pair in Bladder Cancer Develops a Validated Scoring Model for Prognosis and Treatment Response.
    Front Cell Dev Biol. 2022;10:915798.
    PubMed         Abstract available
    
    

    
    Front Genet

40. ZHANG Y, Wang Y, Wang J, Zhang K, et al
    The Immune Cell Infiltration Patterns and Characterization Score in Bladder Cancer to Identify Prognosis.
    Front Genet. 2022;13:852708.
    PubMed         Abstract available
    
    

    
    Front Med (Lausanne)

41. KOLL FJ, Schwarz A, Kollermann J, Banek S, et al
    CK5/6 and GATA3 Defined Phenotypes of Muscle-Invasive Bladder Cancer: Impact in Adjuvant Chemotherapy and Molecular Subtyping of Negative Cases.
    Front Med (Lausanne). 2022;9:875142.
    PubMed         Abstract available
    
    

    
    Front Oncol

42. PANG K, Dong Y, Hao L, Shi ZD, et al
    ERH Interacts With EIF2alpha and Regulates the EIF2alpha/ATF4/CHOP Pathway in Bladder Cancer Cells.
    Front Oncol. 2022;12:871687.
    PubMed         Abstract available
    
    

    
    Gene

43. LIU Z, Liu X, Liu F, Zhao H, et al
    The comprehensive and systematic identification of BLCA-specific SF-regulated, survival-related AS events.
    Gene. 2022;835:146657.
    PubMed         Abstract available
    
    

    
    IJU Case Rep

44. GOTO Y, Tanaka S, Maruo M, Sugawara S, et al
    Pathological complete response of plasmacytoid variant bladder cancer to pembrolizumab following genomic analysis.
    IJU Case Rep. 2022;5:304-307.
    PubMed         Abstract available
    
    

    
    Indian J Surg Oncol

45. KUMAR P, Sharma S, Sundriyal D, Navria SC, et al
    An Institution-Based Demographic Study of Urinary Bladder Cancer from North India.
    Indian J Surg Oncol. 2022;13:432-434.
    PubMed         Abstract available
    
    

    
    Int J Med Robot

46. YANG X, Wang Y, Jiao W, Li J, et al
    Application of 5G technology to conduct tele-surgical robot-assisted laparoscopic radical cystectomy.
    Int J Med Robot. 2022;18:e2412.
    PubMed         Abstract available
    
    

    
    Int J Mol Med

47. JI J, Li H, Chen J, Wang W, et al
    Lamin B2 contributes to the proliferation of bladder cancer cells via activating the expression of cell division cycleassociated protein 3.
    Int J Mol Med. 2022;50.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

48. CHARGARI C, Haie-Meder C, Espenel S, Garcia MA, et al
    Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments.
    Int J Radiat Oncol Biol Phys. 2022;113:602-613.
    PubMed         Abstract available
    
    

    
    Int J Surg Pathol

49. TAKADA-OWADA A, Fuchizawa H, Kijima T, Ishikawa M, et al
    Cryptococcal Prostatitis Forming Caseous and Suppurative Granulomas Diagnosed by Needle Biopsy: A Case Report.
    Int J Surg Pathol. 2022;30:586-589.
    PubMed         Abstract available
    
    

    
    Int J Urol

50. TOGASHI K, Hatakeyama S, Yoneyama T, Hamaya T, et al
    Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
    Int J Urol. 2022;29:733-739.
    PubMed         Abstract available
    
    
51. SARI MOTLAGH R, Schuettfort VM, Mori K, Katayama S, et al
    Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.
    Int J Urol. 2022;29:676-683.
    PubMed         Abstract available
    
    
52. MASTROIANNI R, Simone G
    Editorial Comment to Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.
    Int J Urol. 2022;29:684.
    PubMed        
    
    
53. ISHIYAMA Y
    Editorial Comment to Impact of early postoperative creatinine increase on mid-term renal function after cystectomy.
    Int J Urol. 2022;29:724.
    PubMed        
    
    
54. KITA Y, Ito K, Sano T, Hashimoto K, et al
    Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
    Int J Urol. 2022;29:647-655.
    PubMed         Abstract available
    
    

    
    Investig Clin Urol

55. LEE HW, Seo HK
    Clinical implications and practical considerations for poly-ADP-ribose polymerase inhibitors as a new horizon for the management of urothelial carcinoma of the bladder.
    Investig Clin Urol. 2022;63:369-372.
    PubMed        
    
    

    
    J Adv Res

56. LIU S, Chen X, Lin T
    Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives.
    J Adv Res. 2022;39:187-202.
    PubMed         Abstract available
    
    

    
    J Chromatogr A

57. FANG T, Tang C, Yin J, Wang H, et al
    Magnetic multi-enzyme cascade combined with liquid chromatography tandem mass spectrometry for fast DNA digestion and quantitative analysis of 5-hydroxymethylcytosine in genome of human bladder cancer T24 cells induced by tetrachlorobenzoquinone.
    J Chromatogr A. 2022;1676:463279.
    PubMed         Abstract available
    
    

    
    J Immunother Cancer

58. MOREO E, Uranga S, Pico A, Gomez AB, et al
    Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors.
    J Immunother Cancer. 2022;10.
    PubMed         Abstract available
    
    

    
    J Rheumatol

59. YILDIRIM R, Cansu DU, Korkmaz C
    A Case of Scleromyxedema Development Following Intravesical Bacillus Calmette-Guerin Administration.
    J Rheumatol. 2022;49:858-859.
    PubMed        
    
    

    
    J Transl Med

60. SONG Q, Yu H, Cheng Y, Han J, et al
    Bladder cancer-derived exosomal KRT6B promotes invasion and metastasis by inducing EMT and regulating the immune microenvironment.
    J Transl Med. 2022;20:308.
    PubMed         Abstract available
    
    

    
    Mayo Clin Proc

61. GUPTA S, Erickson LA
    Postirradiation Angiosarcoma of the Urinary Bladder.
    Mayo Clin Proc. 2022;97:1406-1408.
    PubMed        
    
    

    
    Medicine (Baltimore)

62. ZHANG L, Ding D, Liu J, Liu J, et al
    Identification of prognostic and immunotherapy-related eRNA ID2-AS1 in bladder cancer.
    Medicine (Baltimore). 2022;101:e29759.
    PubMed         Abstract available
    
    
63. ZENG W, Swee DS
    Severe and refractory hypocalcaemia secondary to osteoblastic bone metastases in bladder signet ring carcinoma: A case report and literature review.
    Medicine (Baltimore). 2022;101:e29731.
    PubMed         Abstract available
    
    
64. CHEN H, Wang Z, Yang N, Zhang J, et al
    Decorin inhibits proliferation and metastasis in human bladder cancer cells by upregulating P21.
    Medicine (Baltimore). 2022;101:e29760.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

65. MARTIN A, Woolbright BL, Umar S, Ingersoll MA, et al
    Bladder cancer, inflammageing and microbiomes.
    Nat Rev Urol. 2022 Jul 7. pii: 10.1038/s41585-022-00611.
    PubMed         Abstract available
    
    

    
    Oncogene

66. LIU F, Zhang H, Xie F, Tao D, et al
    Correction: Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis.
    Oncogene. 2022 Jul 7. pii: 10.1038/s41388-022-02358.
    PubMed        
    
    

    
    Oncologist

67. GIM G, Kim Y, Park Y, Kim MJ, et al
    Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review.
    Oncologist. 2022;27:525-531.
    PubMed         Abstract available
    
    

    
    Pharmacoepidemiol Drug Saf

68. KEMP-CASEY A, Mintzes B, Morrow RL, Dormuth CR, et al
    Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: an interrupted time series study.
    Pharmacoepidemiol Drug Saf. 2022 Jul 5. doi: 10.1002/pds.5508.
    PubMed         Abstract available
    
    

    
    PLoS Genet

69. CHEN M, Chan RWY, Cheung PPH, Ni M, et al
    Fragmentomics of urinary cell-free DNA in nuclease knockout mouse models.
    PLoS Genet. 2022;18:e1010262.
    PubMed         Abstract available
    
    

    
    PLoS One

70. GULYAS D, Kovacs G, Jankovics I, Meszaros L, et al
    Effects of the combination of a monoclonal agonistic mouse anti-OX40 antibody and toll-like receptor agonists: Unmethylated CpG and LPS on an MB49 bladder cancer cell line in a mouse model.
    PLoS One. 2022;17:e0270802.
    PubMed         Abstract available
    
    
71. GLEICHENHAGEN J, Arndt C, Casjens S, Topfer C, et al
    Exploring solid-phase proximity ligation assay for survivin detection in urine.
    PLoS One. 2022;17:e0270535.
    PubMed         Abstract available
    
    

    
    Sci Rep

72. TAN W, Yuan Y, Huang H, Ma J, et al
    Comprehensive analysis of autophagy related long non-coding RNAs in prognosis, immunity, and treatment of muscular invasive bladder cancer.
    Sci Rep. 2022;12:11242.
    PubMed         Abstract available
    
    

    
    Ther Adv Med Oncol

73. GUO Y, Zheng Z, Zhang W, Mao S, et al
    Gender dimorphism in survival of patients with lymph node metastasis of bladder cancer.
    Ther Adv Med Oncol. 2022;14:17588359221108690.
    PubMed         Abstract available
    
    

    
    World J Surg Oncol

74. XU T, Gu W, Wang X, Xia L, et al
    Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature.
    World J Surg Oncol. 2022;20:226.
    PubMed         Abstract available
    
    

    
    World J Urol

75. PHE V
    Bladder Cancer in Neurogenic Patients.
    World J Urol. 2022 Jul 8. pii: 10.1007/s00345-022-04089.
    PubMed        
    
    
76. RICHTERS A, Leliveld AM, Goossens-Laan CA, Aben KKH, et al
    Sex differences in treatment patterns for non-advanced muscle-invasive bladder cancer: a descriptive analysis of 3484 patients of the Netherlands Cancer Registry.
    World J Urol. 2022 Jul 1. pii: 10.1007/s00345-022-04080.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: